Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon alfa-2a plus ribavirin in HIV-HCV coinfected adults with chronic hepatitis C and normal transaminases
ISRCTN01405766Phase 4Completed
- Sponsor
- Roche
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection and hepatitis C and HIV coinfection (2 arms), sponsored by Roche. Primary endpoint: Sustained virological response. Started May 2006; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionhepatitis C and HIV coinfection
Beyond the preview
Go deeper on ISRCTN01405766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN01405766.